Hemostemix Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HMTXF research report →
About the company
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia.
- CEO
- Thomas A. Smeenk
- IPO
- 2016
- Employees
- 488
- HQ
- Calgary, AB, CA
Price Chart
- Market Cap
- $7.41M
- P/E
- -2.32
- P/S
- 0.00
- P/B
- -1.64
- EV/EBITDA
- -3.71
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 80.07%
- ROIC
- 413.73%
- Revenue
- $0 · 0.00%
- Net Income
- $-4,710,088.7 · -80.05%
- EPS
- $-0.03 · -4.73%
- Op Income
- $-5,628,274
- FCF YoY
- -138.21%
- 52W High
- $0.11
- 52W Low
- $0.04
- 50D MA
- $0.04
- 200D MA
- $0.06
- Beta
- 0.62
- Avg Volume
- 4.13K
Get TickerSpark's AI analysis on HMTXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HMTXF coverage
Recent articles, reports, and earnings notes.
No research on HMTXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HMTXF report →Similar companies
Peers in the same neighborhood.